Pan-cancer survival analysis showed that FBXO5 promoter methylation levels were obviously correlated with better OS in patients diagnosed as ACC, KIRP, LGG, MESO, and SARC, which was opposite in KIRC and LAML patients. The gene discussed is FBXO5; the disease is cancer.